ADAPTIVE THERAPEUTICS - Trademark Details
Status: 602 - Abandoned-Failure To Respond Or Late Response
Serial Number
86663020
Word Mark
ADAPTIVE THERAPEUTICS
Status
602 - Abandoned-Failure To Respond Or Late Response
Status Date
2016-04-27
Filing Date
2015-06-15
Mark Drawing
4000 - Standard character mark
Typeset
Attorney Name
Law Office Assigned Location Code
L10
Employee Name
PEREZ, STEVEN M
Statements
Goods and Services
Scientific and technological services and research and design relating thereto; scientific research, development, engineering, testing, scientific research consultation, and analytical services in the fields of medicine, oncology, hematology, auto-immune disorders, infectious diseases, immunology, immunotherapies, immunopharmaceuticals, immune sequencing, immune repertoire quantitation and sequencing, diagnostics, pharmaceuticals, genetics, gene expression, genetics testing, vaccines and vaccine development, biotechnology, T-cell therapeutics, antibody development and therapeutics, and therapeutic technologies; development of new technology for others in the fields of medicine, oncology, hematology, auto-immune disorders, infectious diseases, immunology, immunotherapies, immunopharmaceuticals, immune sequencing, immune repertoire quantitation and sequencing, diagnostics, pharmaceuticals, genetics, genetics testing, vaccines and vaccine development, biotechnology, T-cell therapeutics, antibody development and therapeutics, and therapeutic technologies; DNA screening and analysis services; genome amplification; genotyping services for research or analysis purposes; medical and scientific research in the fields of cancer biology and diagnosing and treating cancer; providing medical and scientific research information in the field of clinical trials; scientific research in the field of relative and absolute quantitation of adaptive immune cells in a complex biological sample; scientific research for providing relative and absolute quantitation of adaptive immune cells in a solid tumor sample; scientific research for estimating the relative representation of tumor infiltrating T cells in a solid tumor; scientific research for quantifying the presence and clonality of tumor infiltrating lymphocytes in solid tumors; research and development for quantifying the presence and clonality of tumor infiltrating lymphocytes in solid tumors; scientific research, development, engineering, testing, and analytical services for identifying polypeptide pairs of adaptive immune receptor heterodimers of the immune system; scientific research, development, engineering, testing, and analytical services for analyzing and quantifying the diversity of the immune system; scientific research, development, engineering, testing, and analytical services for discovering immune targets; scientific research, engineering, testing, and analytical services for developing monoclonal antibodies and epitope mapping; scientific research for providing sequencing data and analysis of the immune system for vaccine development and vaccine optimization; research and development of vaccines, immunotherapies, and diagnostics; providing technology consultation and research services in the field of immune repertoire analysis, personalized medicine, vaccines, immunotherapies, and diagnostics; scientific research for providing computational analysis of the immune repertoire; providing clinical diagnostic assays and diagnostic or prognostic testing for detection of minimal residual disease in lymphoid malignancies; providing analysis, evaluation, and clinical reports of a patient's immune repertoire, including T cell or B cell clonal diversity and clone frequency; providing assays for tracking clones in an immune repertoire over time; providing diagnostic assays and diagnostic or prognostic testing for residual disease, and the analysis, evaluation, and reports of those test results to help healthcare professionals determine a patient's clinical diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly; research, development, engineering, testing, and analytical services in the fields of vaccines, screening and detecting diseases, medicine, and therapeutics; research and development of vaccines, immunotherapies, medical diagnostics kits, and therapeutics; research and development of diagnostic test kits for screening and detecting diseases; laboratory research and testing services relating to vaccines, screening and detecting diseases, medicine, and therapeutics; computer services; design and development of computer hardware and software; computer services, namely, software as a service (SAAS) services featuring software that provides information, test results for screening and detecting diseases, and the analysis, evaluation, and reporting of those test results to healthcare professionals and patients; research and diagnostic services for identifying antigen-specific T cells for therapeutic use
Goods and Services
Medical services; medical analysis and diagnostic services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; providing medical diagnostic testing for the treatment of cancer; providing medical testing for immune responses to immunotherapy or cancer treatment; providing medical quantitative analysis and testing services in the fields of cancer biology, immunology, pharmaceuticals and vaccines for diagnostic or treatment purposes; medical testing for the prognosis and staging of patients with solid tumors for treatment purposes; therapeutic services; therapeutic services for the treatment of diseases; therapeutic services for the treatment of cancer
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2015-06-18
Primary Code
042
International Class
044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2015-06-18
Primary Code
044
Correspondences
Name
HOANG-CHI TRUONG
Address
Please log in with your Justia account to see this address.
Madrid International Filings
Entry Number
1
Reference Number
A0054722
Original Filing Date USPTO
2015-11-17
International Registration Number
1281407
International Registration Date
2015-11-17
International Status Code
499
International Renewal Date
2025-11-17
Madrid History Events | ||
Date | Code | Description |
2016-04-28 | PRINX | INTERNATIONAL REGISTRATION CANCELLED BY IB |
2015-11-17 | NEWAP | NEW APPLICATION FOR IR RECEIVED |
2015-11-17 | ACERT | AUTOMATICALLY CERTIFIED |
2015-11-17 | APPST | IR CERTIFIED AND SENT TO IB |
2016-01-03 | CREAT | APPLICATION FOR IR REGISTERED BY IB |
Trademark Events
Event Date | Event Description |
2015-06-18 | NEW APPLICATION ENTERED IN TRAM |
2015-06-18 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2015-09-23 | ASSIGNED TO EXAMINER |
2015-09-30 | NON-FINAL ACTION WRITTEN |
2015-09-30 | NON-FINAL ACTION E-MAILED |
2015-09-30 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2016-04-27 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
2016-04-27 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
2018-02-13 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |